Moreover, O‐GlcNAcylation of SREBP‐1 plays a crucial role in changing hepatic lipid synthesis and the progression of fatty liver disease.[30] Inhibition of O‐GlcNAcylation of nuclear factor‐κB (NF‐κB) has been found to reduce hepatic steatosis.[31] Our research aligns with these findings, demonstrating that inhibiting O‐GlcNAcylation with BAGN effectively inhibits lipid accumulation, inflammation, and collagen deposition, and promotes liver function recovery in HFD‐fed and CDAHFD‐fed mice. The gene discussed is NFKB1; the disease is fatty liver disease.